Stock Track | Nuvation Bio Soars 5.50% in Post-Market on Positive Analyst Ratings and Maintained Buy Recommendations

Stock Track
03/04

Nuvation Bio Inc. (NUVB) experienced a significant surge of 5.50% during post-market trading on Tuesday, reflecting positive investor sentiment following recent analyst actions.

The stock's upward movement appears to be driven by favorable analyst coverage, including Wedbush maintaining its Buy rating on Nuvation Bio with a price target of $11.00. Analyst David Nierengarten from Wedbush continued to express confidence in the company's prospects despite broader market challenges in the healthcare sector.

Additionally, market data indicates that Nuvation Bio maintains an average rating of "Buy" among analysts, with a mean price target of $11.60 according to FactSet polling. This positive analyst sentiment, particularly the maintained Buy rating from Wedbush with a target significantly above current trading levels, likely contributed to the stock's post-market surge as investors responded to the optimistic outlook.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10